Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 201 to 250 of 314 results for breast cancer

  1. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (HTG171)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

    HealthTech guidance
    Published
    23 July 2008
    View recommendations

    Sections for HTG171

  2. Laparoscopic mobilisation of the greater omentum for breast reconstruction (HTG162)

    Evidence-based recommendations on laparoscopic mobilisation of the greater omentum for breast reconstruction. This involves removing the fatty tissue using special instruments through small cuts in the abdomen.

    HealthTech guidance
    Published
    27 February 2008
    View recommendations

    Sections for HTG162

  3. Gemcitabine for the treatment of metastatic breast cancer (TA116)

    Evidence-based recommendations on gemcitabine for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    24 January 2007
    View recommendations

    Sections for TA116

  4. Image-guided vacuum-assisted excision biopsy of benign breast lesions (HTG100)

    Evidence-based recommendations on image-guided vacuum-assisted excision biopsy for benign breast lesions. This involves inserting a needle with a suction device through a small opening in the breast to remove non-cancerous lumps.

    HealthTech guidance
    Published
    22 February 2006
    View recommendations

    Sections for HTG100

  5. Endoscopic axillary lymph node retrieval for breast cancer (HTG93)

    Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.

    HealthTech guidance
    Published
    14 December 2005
    View recommendations

    Sections for HTG93

  6. Interstitial laser therapy for breast cancer (HTG55)

    Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.

    HealthTech guidance
    Published
    22 September 2004
    View recommendations

    Sections for HTG55

  7. Tacrolimus and pimecrolimus for atopic eczema (TA82)

    Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.

    Technology appraisal guidance
    Published
    25 August 2004
    View recommendations

    Sections for TA82

  8. Guidance on the use of trastuzumab for the treatment of advanced breast cancer (TA34)

    Evidence-based recommendations on trastuzumab for treating advanced breast cancer in adults.

    Technology appraisal guidance
    Published
    15 March 2002
    View recommendations

    Sections for TA34

  9. Breast cancer guidelines

    This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to the...

    NICE guideline
    In development

  10. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued Reference number: GID-TA10531

    Technology appraisal guidance
    Discontinued

  11. Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]

    Discontinued Reference number: GID-TA10539

    Technology appraisal guidance
    Discontinued

  12. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued Reference number: GID-TA10570

    Technology appraisal guidance
    Discontinued

  13. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued Reference number: GID-TA10591

    Technology appraisal guidance
    Discontinued

  14. Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]

    In development Reference number: GID-TA10592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

    Discontinued Reference number: GID-TA10803

    Technology appraisal guidance
    Discontinued

  16. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development Reference number: GID-TA10896 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  17. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]

    Discontinued Reference number: GID-TA11178

    Technology appraisal guidance
    Discontinued

  19. Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

    Awaiting development Reference number: GID-TA10723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  20. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued Reference number: GID-TA11261

    Technology appraisal guidance
    Discontinued

  21. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  22. Intensity modulated radiotherapy for breast cancer [ID16]

    Discontinued Reference number: GID-TAG390

    Technology appraisal guidance
    Discontinued

  23. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  24. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued Reference number: GID-TAG403

    Technology appraisal guidance
    Discontinued

  25. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  26. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development Reference number: GID-TA11165 Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued Reference number: GID-TAG411

    Technology appraisal guidance
    Discontinued

  28. Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]

    Discontinued Reference number: GID-TAG417

    Technology appraisal guidance
    Discontinued

  29. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued Reference number: GID-TAG432

    Technology appraisal guidance
    Discontinued

  30. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued Reference number: GID-TAG436

    Technology appraisal guidance
    Discontinued

  31. Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]

    In development Reference number: GID-TA11273 Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Everolimus with exemestane for treating HER2-negative hormone-receptor-positive breast cancer after endocrine therapy [ID965]

    Discontinued Reference number: GID-TA10028

    Technology appraisal guidance
    Discontinued

  33. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

    Technology appraisal guidance
    Discontinued

  34. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development

  35. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development Reference number: GID-TA10261 Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy [ID1347]

    Discontinued Reference number: GID-TA10264

    Technology appraisal guidance
    Discontinued

  37. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592]

    Awaiting development Reference number: GID-TA11769 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  39. Digital AI tools in histopathology (breast and prostate cancer)

    Awaiting development Reference number: GID-HTE10087 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  40. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development Reference number: GID-TA11089 Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

    In development Reference number: GID-TA11658 Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development Reference number: GID-TA11400 Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Artificial intelligence technologies for mammography: early value assessment

    Awaiting development Reference number: GID-HTE10062 Expected publication date: TBC

    Health technology evaluations
    Awaiting development

  44. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]

    Awaiting development Reference number: GID-TA11720 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  46. Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]

    Awaiting development Reference number: GID-TA11724 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  47. Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]

    In development Reference number: GID-TA11402 Expected publication date: TBC

    Technology appraisal guidance
    In development

  48. Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]

    Discontinued Reference number: GID-TA11339

    Technology appraisal guidance
    Discontinued

  49. Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769]

    Awaiting development Reference number: GID-TA11088 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  50. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    Discontinued Reference number: GID-TA11318

    Technology appraisal guidance
    Discontinued